

Part VI: Summary of the risk management plan for Carbimazole Orifarm

This is a summary of the risk management plan (RMP) for Carbimazole Orifarm. The RMP details important risks of Carbimazole Orifarm how these risks can be minimised, and how more information will be obtained about Carbimazole Orifarm's risks and uncertainties(missing information).

Carbimazole Orifarm's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Carbimazole Orifarm should be used.

I. The medicine and what it is used for

Carbimazole Orifarm is authorised for long-term treatment of thyrotoxicosis, Basedow's disease (Graves' disease) and therapy prior to radio-iodine treatment or preparation for thyroidectomy (see SmPC for the full indication). It contains carbimazole as the active substances and it is given orally as tablets.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Carbimazole Orifarm, together with measures to minimise such risks and the proposed studies for learning more about Carbimazole Orifarm's risks, are outlines below.

- Product information including warnings, precautions, and advice on correct use. Package leaflet is enclosed in the package and the Summary of Product Characteristics (and Package Leaflet) are published on the webpage of the Danish, Norwegian and Icelandic Medicines Agency.
- The medicine's is prescription only medicine and must be prescribed by a doctor.

Together, these measures constitute *routine risk minimisation* measures.

If important information that may affect the safe use of Carbimazole Orifarm is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Carbimazole Orifarm are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Carbimazole Orifarm. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

Summary of safety concerns	
Important identified risks	None
Important potential risks	<ul style="list-style-type: none">• Birth defects and neonatal disorders in case of exposure during pregnancy
Missing information	None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Carbimazole Orifarm.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Carbimazole Orifarm.